GlassScriptPhysician profile
Joseph T Belleau
NPI 1346297371
$12,307.22
in general payments reported to CMS, 2019-2025
32 companies · $2,561 in 2025
The $2,561 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $978 · 2021: $1,820 · 2022: $2,078 · 2023: $1,727 · 2024: $2,141 · 2025: $2,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,385 · Education: $23.02 · Consulting Fee: $20.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,385.38 |
| Education | $23.02 |
| Consulting Fee | $20.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,998.49 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,396.92 | 2019-2025 | |
| Csl Behring | $1,314.22 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,085.70 | 2019-2023 | Trelegy Ellipta, Nucala, Shingrix |
| Amgen INC. | $717.49 | 2022-2025 | Tezspire |
| Pfizer INC. | $685.55 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $685.53 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $677.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $493.27 | 2021-2025 | Cuvitru, Eohilia, Takhzyro |
| Optinose US, INC. | $471.08 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $466.96 | 2025 | Neffy |
| Kaleo, INC. | $406.27 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $364.85 | 2019-2025 | Xolair |
| Grifols USA, LLC | $338.52 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $202.01 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $191.02 | 2019-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.99 | 2019-2022 | |
| Alk-Abello, INC | $137.00 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Hikma Pharmaceuticals USA | $97.54 | 2022-2024 | Ryaltris |
| Octapharma USA, INC. | $97.52 | 2021-2025 | Cutaquig |
| Lilly USA, LLC | $59.88 | 2024-2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $42.66 | 2021-2023 | |
| Greer Laboratories, INC. | $39.89 | 2019-2025 | Oralair |
| Eyevance Pharmaceuticals LLC | $30.26 | 2020 | |
| Aimmune Therapeutics, INC. | $27.45 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $23.71 | 2023 | Orladeyo |
| Shire North American Group INC | $22.38 | 2019 | |
| Adma Biomanufacturing LLC | $20.98 | 2024 | |
| Galderma Laboratories, L.P. | $18.57 | 2025 | Nemluvio |
| Azurity Pharmaceuticals, INC. | $16.24 | 2025 | Alvesco |
| Phadia US INC. | $14.79 | 2024 | Immunocap |
| Allergan, INC. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Belleau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.